{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:38:07Z","timestamp":1792269487888,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,30]]},"DOI":"10.7759\/cureus.115436","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T13:26:20Z","timestamp":1788096380000},"source":"Crossref","is-referenced-by-count":1,"title":["Flagellate Erythema Induced by a Low Cumulative Dose of Bleomycin: A Case Report"],"prefix":"10.7759","author":[{"given":"Kiley B","family":"Kirby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Dermatology, 5th Edition","author":"Bolognia J","year":"2024","unstructured":"Bolognia J, Schaffer JV, Lorenzo Cerroni L. Dermatology, 5th Edition. Elsevier, Amsterdam, Netherlands; 2024."},{"key":"ref2","article-title":"Bleomycin and other antitumor antibiotics of high molecular weight","volume":"5","author":"Umezawa H","year":"1965","unstructured":"Umezawa H. Bleomycin and other antitumor antibiotics of high molecular weight. Antimicrob Agents Chemother (Bethesda). 1965, 5:1079-85.","journal-title":"Antimicrob Agents Chemother (Bethesda)"},{"key":"ref3","unstructured":"National Cancer Institute. Bleomycin sulfate. (2009). Accessed. April 5, 2026: https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/bleomycin."},{"key":"ref4","article-title":"Bleomycin","author":"Brandt JP","year":"2026","unstructured":"Brandt JP, Gerriets V. Bleomycin. StatPearls [Internet].  StatPearls Publishing, Treasure Island (FL); 2026."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2019.04.003","article-title":"Current management of disseminated germ cell tumors","volume":"46","author":"Lavoie JM","year":"2019","unstructured":"Lavoie JM, Kollmannsberger CK. Current management of disseminated germ cell tumors. Urol Clin North Am. 2019, 46:377-88. 10.1016\/j.ucl.2019.04.003","journal-title":"Urol Clin North Am"},{"key":"ref6","article-title":"Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics","volume":"19","author":"Dorr RT","year":"1992","unstructured":"Dorr RT. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin Oncol. 1992, 19:3-8.","journal-title":"Semin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000001271","article-title":"Histological features of flagellate erythema","volume":"41","author":"Ching D","year":"2019","unstructured":"Ching D, Wood BA, Tiwari S, Chan J, Harvey NT. Histological features of flagellate erythema. Am J Dermatopathol. 2019, 41:410-21. 10.1097\/DAD.0000000000001271","journal-title":"Am J Dermatopathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2165\/11537080-000000000-00000","article-title":"Flagellate dermatitis as a bleomycin-specific adverse effect of cytostatic therapy: a clinical-histopathologic correlation","volume":"12","author":"Ziemer M","year":"2011","unstructured":"Ziemer M, Goetze S, Juhasz K, Elsner P. Flagellate dermatitis as a bleomycin-specific adverse effect of cytostatic therapy: a clinical-histopathologic correlation. Am J Clin Dermatol. 2011, 12:68-76. 10.2165\/11537080-000000000-00000","journal-title":"Am J Clin Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13719","article-title":"Four cycles of etoposide plus cisplatin for patients with good-risk advanced germ cell tumors","volume":"26","author":"Funt SA","year":"2021","unstructured":"Funt SA, McHugh DJ, Tsai S, et al.. Four cycles of etoposide plus cisplatin for patients with good-risk advanced germ cell tumors. Oncologist. 2021, 26:483-91. 10.1002\/onco.13719","journal-title":"Oncologist"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1994.tb04986.x","article-title":"Bleomycin-induced flagellate dermatitis: a clinical and histopathological review","volume":"131","author":"Mowad CM","year":"1994","unstructured":"Mowad CM, Nguyen TV, Elenitsas R, Leyden JJ. Bleomycin-induced flagellate dermatitis: a clinical and histopathological review. Br J Dermatol. 1994, 131:700-2. 10.1111\/j.1365-2133.1994.tb04986.x","journal-title":"Br J Dermatol"},{"key":"ref11","article-title":"'Flagellate' erythema from bleomycin. With histopathological findings suggestive of inflammatory oncotaxis","volume":"180","author":"Cortina P","year":"1990","unstructured":"Cortina P, Garrido JA, Tomas JF, Unamuno P, Armijo M. 'Flagellate' erythema from bleomycin. With histopathological findings suggestive of inflammatory oncotaxis. Dermatologica. 1990, 180:106-10.","journal-title":"Dermatologica"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7727\/wimj.2014.060","article-title":"Bleomycin-induced flagellate erythema: a rare and unique drug rash","volume":"63","author":"Changal KH","year":"2014","unstructured":"Changal KH, Raina H, Changal QH, Raina M. Bleomycin-induced flagellate erythema: a rare and unique drug rash. West Indian Med J. 2014, 63:807-9. 10.7727\/wimj.2014.060","journal-title":"West Indian Med J"},{"key":"ref13","unstructured":"An Online Catalog of Human Genes and Genetic Disorders. Bleomyc\u0131n hydrolase; BLMH. (2025). Accessed. August 24, 2026: https:\/\/omim.org\/entry\/602403."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.3.337","article-title":"Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris","volume":"139","author":"Abess A","year":"2003","unstructured":"Abess A, Keel DM, Graham BS. Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. Arch Dermatol. 2003, 139:337-9. 10.1001\/archderm.139.3.337","journal-title":"Arch Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.8.4680","article-title":"The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance","volume":"96","author":"Schwartz DR","year":"1999","unstructured":"Schwartz DR, Homanics GE, Hoyt DG, Klein E, Abernethy J, Lazo JS. The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance. Proc Natl Acad Sci U S A. 1999, 96:4680-5. 10.1073\/pnas.96.8.4680","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref16","unstructured":"U.S. National Library of Medicine. Bleomycin powder, for solution. (2026). Accessed. May 4, 2026: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=6824b1e1-e5fa-4371-ade9-1346e12ab0c7."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/495366-flagellate-erythema-induced-by-a-low-cumulative-dose-of-bleomycin-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T13:26:22Z","timestamp":1788096382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/495366-flagellate-erythema-induced-by-a-low-cumulative-dose-of-bleomycin-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.115436","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,30]]}}}